The EDGE

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review

H Walter and A L Thomas

Br J Cancer 2013 108: 2417-2418; 10.1038/bjc.2013.244

Minireviews

Long noncoding RNAs and the genetics of cancer

S W Cheetham, F Gruhl, J S Mattick and M E Dinger

Br J Cancer 2013 108: 2419-2425; advance online publication, May 9, 2013; 10.1038/bjc.2013.233

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer

E S Lianidou, D Mavroudis and V Georgoulias

Br J Cancer 2013 108: 2426-2432; advance online publication, June 11, 2013; 10.1038/bjc.2013.265

Clinical Studies

What is a virtual multidisciplinary team (vMDT)?

A J Munro and S Swartzman

Br J Cancer 2013 108: 2433-2441; advance online publication, June 11, 2013; 10.1038/bjc.2013.231

Multidisciplinary decisions in breast cancer: does the patient receive what the team has recommended?

S Rajan, J Foreman, M G Wallis, C Caldas and P Britton

Br J Cancer 2013 108: 2442-2447; advance online publication, June 4, 2013; 10.1038/bjc.2013.267

Multicentre external validation of IOTA prediction models and RMI by operators with varied training

A Sayasneh, L Wynants, J Preisler, J Kaijser, S Johnson, C Stalder, R Husicka, Y Abdallah, F Raslan, A Drought, A A Smith, S Ghaem-Maghami, E Epstein, B Van Calster, D Timmerman and T Bourne

Br J Cancer 2013 108: 2448-2454; advance online publication, May 14, 2013; 10.1038/bjc.2013.224

Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004

A MacCarthy, A M Bayne, P A Brownbill, K J Bunch, N L Diggens, G J Draper, M M Hawkins, H C Jenkinson, J E Kingston, C A Stiller, T J Vincent and M F G Murphy

Br J Cancer 2013 108: 2455-2463; advance online publication, May 14, 2013; 10.1038/bjc.2013.228

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer

M McCormack, L Kadalayil, A Hackshaw, M A Hall-Craggs, R P Symonds, V Warwick, H Simonds, I Fernando, M Hammond, L James, A Feeney and J A Ledermann

Br J Cancer 2013 108: 2464-2469; advance online publication, May 21, 2013; 10.1038/bjc.2013.230

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma

R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak and M E Gore

Br J Cancer 2013 108: 2470-2477; advance online publication, May 21, 2013; 10.1038/bjc.2013.236

Translational Therapeutics

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

M D Kaymakcalan, Y Je, G Sonpavde, M Galsky, P L Nguyen, D Y C Heng, C J Richards and T K Choueiri

Br J Cancer 2013 108: 2478-2484; advance online publication, June 4, 2013; 10.1038/bjc.2013.278

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma

E Pasquier, J Street, C Pouchy, M Carre, A J Gifford, J Murray, M D Norris, T Trahair, N Andre and M Kavallaris

Br J Cancer 2013 108: 2485-2494; advance online publication, May 21, 2013; 10.1038/bjc.2013.205

p28, A first in class peptide inhibitor of cop1 binding to p53

T Yamada, K Christov, A Shilkaitis, L Bratescu, A Green, S Santini, A R Bizzarri, S Cannistraro, T K D Gupta and C W Beattie

Br J Cancer 2013 108: 2495-2504; advance online publication, June 4, 2013; 10.1038/bjc.2013.266

Molecular Diagnostics

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

A Loganayagam, M Arenas Hernandez, A Corrigan, L Fairbanks, C M Lewis, P Harper, N Maisey, P Ross, J D Sanderson and A M Marinaki

Br J Cancer 2013 108: 2505-2515; advance online publication, June 4, 2013; 10.1038/bjc.2013.262

Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion

M Nakada, E Nambu, N Furuyama, Y Yoshida, T Takino, Y Hayashi, H Sato, Y Sai, T Tsuji, K-i Miyamoto, A Hirao and J-i Hamada

Br J Cancer 2013 108: 2516-2524; advance online publication, May 7, 2013; 10.1038/bjc.2013.218

Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature

L D′Amico, S Patanè, C Grange, B Bussolati, C Isella, L Fontani, L Godio, M Cilli, P D′Amelio, G Isaia, E Medico, R Ferracini and I Roato

Br J Cancer 2013 108: 2525-2536; 10.1038/bjc.2013.271

Expression of neutrophil gelatinase-associated lipocalin in colorectal neoplastic progression: a marker of malignant potential?

M H McLean, A J Thomson, G I Murray, N Fyfe, G L Hold and E M El-Omar

Br J Cancer 2013 108: 2537-2541; advance online publication, June 4, 2013; 10.1038/bjc.2013.264

The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis

X Xing, W Cai, H Shi, Y Wang, M Li, J Jiao and M Chen

Br J Cancer 2013 108: 2542-2548; advance online publication, May 23, 2013; 10.1038/bjc.2013.251

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

F Loupakis, M Schirripa, C Caparello, N Funel, L Pollina, E Vasile, C Cremolini, L Salvatore, M Morvillo, C Antoniotti, F Marmorino, G Masi and A Falcone

Br J Cancer 2013 108: 2549-2556; advance online publication, May 23, 2013; 10.1038/bjc.2013.245

Somatostatin Receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer

J Zhao, Q Liang, K-F Cheung, W Kang, Y Dong, R W-M Lung, J H-M Tong, K-F To, J J Y Sung and J Yu

Br J Cancer 2013 108: 2557-2564; advance online publication, May 30, 2013; 10.1038/bjc.2013.263

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

C de la Piedra, A Alcaraz, J Bellmunt, C Meseguer, A Gómez-Caamano, M J Ribal, F Vázquez, U Anido, P Samper, E Esteban, J L Álvarez-Ossorio, P C Lara, L A San José, J A Contreras, A G del Alba, B González-Gragera, A J Tabernero, C González-Enguita, J M Fernández, A García-Escudero, F Gómez-Veiga, M J Méndez, J Segarra, J A Virizuela, J Carles, A Lassa, V Calderero, M Constela, D Delgado, A Mañas, A Murias, G Reynes, B Rodriguez, G Rubio, E Sánchez, M Unda, E Solsona, J M Martínez-Javaloyas, J Comet-Batlle, C Quicios, M Martín-Fernández, I Mahillo-Fernández and J Morote

Br J Cancer 2013 108: 2565-2572; advance online publication, May 30, 2013; 10.1038/bjc.2013.270

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients

M Avgeris, K Stravodimos, E G Fragoulis and A Scorilas

Br J Cancer 2013 108: 2573-2581; advance online publication, May 23, 2013; 10.1038/bjc.2013.250

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer

J Cuzick, Z H Yang, G Fisher, E Tikishvili, S Stone, J S Lanchbury, N Camacho, S Merson, D Brewer, C S Cooper, J Clark, D M Berney, H Møller, P Scardino and Z Sangale on behalf of the Transatlantic Prostate Group

Br J Cancer 2013 108: 2582-2589; advance online publication, May 21, 2013; 10.1038/bjc.2013.248

Genetics and Genomics

Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway

P Pandey, P Seshacharyulu, S Das, S Rachagani, M P Ponnusamy, Y Yan, S L Johansson, K Datta, M Fong Lin and S K Batra

Br J Cancer 2013 108: 2590-2600; advance online publication, April 18, 2013; 10.1038/bjc.2013.160

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles

C Cybulski, D Wokołorczyk, W Kluźniak, A Kashyap, A Gołąb, M Słojewski, A Sikorski, M Puszyński, M Soczawa, T Borkowski, A Borkowski, A Antczak, J Przybyła, M Sosnowski, B Małkiewicz, R Zdrojowy, P Domagała, K Piotrowski, J Menkiszak, K Krzystolik, J Gronwald, A Jakubowska, B Górski, T Dębniak, B Masojć, T Huzarski, K R Muir, A Lophatananon, J Lubiński and S A Narod the Polish Hereditary Prostate Cancer Consortium

Br J Cancer 2013 108: 2601-2609; advance online publication, May 30, 2013; 10.1038/bjc.2013.261

Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer

D R Barnes, D Barrowdale, J Beesley, X Chen, kConFab Investigators, Australian Ovarian Cancer Study Group, P A James, J L Hopper, D Goldgar, G Chenevix-Trench, A C Antoniou and G Mitchell

Br J Cancer 2013 108: 2610-2622; advance online publication, June 11, 2013; 10.1038/bjc.2013.277

Letters to the Editor

Merkel cell polyomavirus and non-small cell lung cancer

M Shuda, H Feng, P S Moore and Y Chang

Br J Cancer 2013 108: 2623; advance online publication, June 4, 2013; 10.1038/bjc.2013.195

Integrated and mutated forms of Merkel cell polyomavirus in non-small cell lung cancer

Y Hashida, M Imajoh and M Daibata

Br J Cancer 2013 108: 2624; advance online publication, June 4, 2013; 10.1038/bjc.2013.196

Comment on ‘Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients’: neutrophil to lymphocyte ratio may be predictor of mortality in patients with soft-tissue sarcoma

S Balta, S Demirkol, H Sarlak and O Kurt

Br J Cancer 2013 108: 2625-2626; advance online publication, June 4, 2013; 10.1038/bjc.2013.275

Reply: Comment on ‘Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients’

J Szkandera, M Pichler, A Gerger and A Leithner

Br J Cancer 2013 108: 2627; advance online publication, June 4, 2013; 10.1038/bjc.2013.276

Comment on ‘Psychological distress in patients with cancer: is screening the effective solution?’

J Dekker, A T F Beekman, A D Boenink, H Bomhof-Roordink, A M Braamse, E H Collette, P C Huijgens, M H M van der Linden, B van Meijel, F J Snoek, O Visser and H M Verheul

Br J Cancer 2013 108: 2628-2630; advance online publication, June 11, 2013; 10.1038/bjc.2013.286

Reply: Comment on ‘Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage’ – Psychological distress in patients with cancer: is screening the effective solution?

L E Carlson, A Waller, S L Groff and B D Bultz

Br J Cancer 2013 108: 2631-2632; advance online publication, June 11, 2013; 10.1038/bjc.2013.287

indexes

Author Index for Volume 108

Br J Cancer 2013 108: 2633-2642; 10.1038/bjc.2013.327

Keyword Index for Volume 108

Br J Cancer 2013 108: 2643-2646; 10.1038/bjc.2013.328

Inexes

Referee Acknowledgement for 2012

Br J Cancer 2013 108: 2647-2652; 10.1038/bjc.2013.329